-
Tytuł:
-
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma.
-
Autorzy:
-
Echevarría‐Vargas, Ileabett M.
Reyes‐Uribe, Patricia I.
Guterres, Adam N.
Yin, Xiangfan
Kossenkov, Andrew V.
Liu, Qin
Zhang, Gao
Krepler, Clemens
Cheng, Chaoran
Wei, Zhi
Somasundaram, Rajasekharan
Karakousis, Giorgos
Xu, Wei
Morrissette, Jennifer J. D.
Lu, Yiling
Mills, Gordon B.
Sullivan, Ryan J.
Benchun, Miao
Frederick, Dennie T.
Boland, Genevieve
-
Źródło:
-
EMBO Molecular Medicine; May2018, Vol. 10 Issue 5, p1-1, 15p
-
Abstract: Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are overexpressed in NRAS‐mutant melanoma and that high levels of the BET family member BRD4 are associated with poor patient survival. Combining BET and MEK inhibitors synergistically curbed the growth of NRAS‐mutant melanoma and prolonged the survival of mice bearing tumors refractory to MAPK inhibitors and immunotherapy. Transcriptomic and proteomic analysis revealed that combining BET and MEK inhibitors mitigates a MAPK and checkpoint inhibitor resistance transcriptional signature, downregulates the transcription factor TCF19, and induces apoptosis. Our studies demonstrate that co‐targeting MEK and BET can offset therapy resistance, offering a salvage strategy for melanomas with no other therapeutic options, and possibly other treatment‐resistant tumor types. [ABSTRACT FROM AUTHOR]
Copyright of EMBO Molecular Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)